Lancet (London, England)
Tabata et al., 1999) are illustrative for the pertinence of the poorly resolved problem, illustrative for the diversity of the carriers (i.e., hyaluronate gel carrier (Wang and Aspengberg, 1996), alginate/heparinsacharose microspheres and films (Yu et al., 1998), cellulose gel (Thorn and Aspenberg, 1993), defective form of Pseudomonas exotoxin (Siegall et al., 1994), fibrin adhesive carrier (Walter et al., 1996), biodegredable hydrogen gelatin (Tabata et al., 1999), natural coral, and collagen (Sikiric et al., 2018), there is an inescapable diversity of the carriers and thereby, an evident diversity of the obtained beneficial effects, and disable conclusion
D., & Kerppola, T
To further determine whether UFL1 directly binds to AKT1, we performed in vitro GST pull-down assays using purified GST-AKT1 and immunoprecipitated UFL1 from breast cancer cells
& Kjaerheim, K
Some individuals may not respond to NAC, and benefits, if any, are likely to be modest compared to established interventions